Monthly Publication Highlight - Dr. Michael Kays

Dr. Michael Kays

November 2016 - The Purdue College of Pharmacy is pleased to honor and recognize the outstanding research and scholarship generated by our faculty each month. This month, we highlight Dr. Michael Kays, Associate Professor of Pharmacy Practice.

Dr. Kays’ recent publication, “Population Pharmacokinetics and Pharmacodynamics of Meropenem in Non-Obese, Obese, and Morbidly Obese Patients”, can be read in The Journal of Clinical Pharmacology (DOI: 10.1002/jcph.812, August 17, 2016). The work was completed in collaboration with Eun Kyoung Chung, PharmD, PhD; S. Christian Cheatham, PharmD; Megan R. Fleming, PharmD; and Daniel P. Healy, PharmD. The study was conducted at Indiana University Health Methodist Hospital and Franciscan St. Francis Health in Indianapolis.

Obesity is a global health crisis, and the prevalence of obesity is increasing in many countries. However, appropriate dosing regimens for many drugs, including antibiotics, in obesity are not known, and clinicians may arbitrarily increase the antibiotic dose in these patients. The ultimate goal of this study was to determine appropriate dosing regimens of meropenem, a carbapenem antibiotic frequently used in the treatment of serious bacterial infections, in hospitalized patients who are non-obese, obese, and morbidly obese. We studied 40 patients who required treatment for a suspected or documented bacterial infection. Despite significant differences in total body weights and body mass indexes, there were no significant differences in pharmacokinetic parameters among the patient groups. As a result, standard FDA-approved dosing regimens provide comparable pharmacodynamic exposures for susceptible pathogens in non-obese, obese, and morbidly obese patients. Prolonged infusions of larger doses may be needed if more aggressive pharmacodynamic exposures are desired. Dosage adjustments for meropenem based solely on body weight are unnecessary.

“I became interested in antibiotic dosing in obesity several years ago when I was unable to find any published dosing recommendations to provide guidance for the treatment of a patient who was morbidly obese,” comments Dr. Kays. “My colleagues and I have now studied several common antibiotics in obesity and have provided dosing recommendations for these drugs. We take great pride in knowing that our research in obesity is helping clinicians provide better care for these patients worldwide.”


Mega Menu Visual Content